STUDY SEARCH RESULTS

1 study found for your search request:  3475-937

Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants wi...
Condition: Hepatocellular Carcinoma
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT03867084
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site